Stay updated with the latest stock market news and insights
Weekly insights + SMS alerts
HUTCHMED (China) Limited (NASDAQ: HCM) is having a good day. The biopharma's stock is surging after it announced an exclusive licensing agreement with GSK plc (NYSE: GSK) for its cancer drug candidate, HMPL-A830.
Here's the deal: a GSK subsidiary gets exclusive rights to develop and commercialize the therapy globally, except for Mainland China, Hong Kong, Macau, and Taiwan. Those territories stay with HUTCHMED.
Financially, this is a big one. HUTCHMED gets a $110 million upfront payment from GSK. But that's just the beginning. The company could also earn up to $1.185 billion in future development, regulatory, and commercial milestones. That brings the maximum deal value to $1.295 billion. Plus, GSK will pay tiered royalties based on annual net sales.
Of course, the upfront payment isn't a done deal yet. It's subject to standard closing conditions and antitrust regulatory reviews. So, a bit of paperwork remains.
So, what is HMPL-A830? It's an Antibody-Targeted Therapy Conjugate (ATTC). That's a fancy way of saying it's a smart drug. It attaches a highly selective KRAS inhibitor to an anti-EGFR antibody. The idea is to deliver the inhibitor directly into EGFR-expressing tumors.
By blocking both signaling pathways at once, the therapy aims to be more tolerable, durable, and effective. The clinical focus is on lung, pancreatic, and colorectal cancers. These are the cancers with the highest rates of KRAS-altered tumors, and they've been tough to treat with lasting results.
For now, HUTCHMED is in the driver's seat for the global Phase I development program. It expects to launch trials in the latter half of 2026. After that, GSK takes over for subsequent clinical development and commercialization outside the retained Chinese territories.
HUTCHMED keeps full rights in Mainland China, Hong Kong, Macau, and Taiwan. And there's a little extra: the contract gives GSK first negotiation rights for an earlier-stage ATTC drug candidate. So, this could be the start of a longer relationship.
Investors clearly like what they see. HUTCHMED shares were up 17.94% to $13.60 at the time of publication on Thursday. That's a solid pop for a single announcement.
This deal is a big vote of confidence in HUTCHMED's science, and it gives the company a hefty cash infusion to keep pushing its pipeline forward. For GSK, it's a chance to add a promising cancer therapy to its portfolio. We'll see how the trials go, but for now, it's a win-win on paper.
Real-time alerts on price moves, news, and trading opportunities.
Join 20,000+ investors. No spam, ever.
